BACKGROUND: Proton pump inhibitors are used extensively for acid-related gastrointestinal diseases. Their effect on cardiac contractility has not been assessed directly. METHODS AND RESULTS: Under physiological conditions (37 degrees C, pH 7.35, 1.25 mmol/L Ca2+), there was a dose-dependent decrease in contractile force in ventricular trabeculae isolated from end-stage failing human hearts superfused with pantoprazole. The concentration leading to 50% maximal response was 17.3+/-1.3 microg/mL. Similar observations were made in trabeculae from human atria, normal rabbit ventricles, and isolated rabbit ventricular myocytes. Real-time polymerase chain reaction demonstrated the expression of gastric H+/K+-adenosine triphosphatase in human and rabbit myocardium. However, measurements with BCECF-loaded rabbit trabeculae did not reveal any significant pantoprazole-dependent changes of pH(i). Ca2+ transients recorded from field-stimulated fluo 3-loaded myocytes (F/F0) were significantly depressed by 10.4+/-2.1% at 40 microg/mL. Intracellular Ca2+ fluxes were assessed in fura 2-loaded, voltage-clamped rabbit ventricular myocytes. Pantoprazole (40 microg/mL) caused an increase in diastolic [Ca2+]i by 33+/-12%, but peak systolic [Ca2+]i was unchanged, resulting in a decreased Ca2+ transient amplitude by 25+/-8%. The amplitude of the L-type Ca2+ current (I(Ca,L)) was reduced by 35+/-5%, and sarcoplasmic reticulum Ca2+ content was reduced by 18+/-6%. Measurements of oxalate-supported sarcoplasmic reticulum Ca2+ uptake in permeabilized cardiomyocytes indicated that pantoprazole decreased Ca2+ sensitivity (Kd) of sarcoplasmic reticulum Ca2+ adenosine triphosphatase: control, Kd=358+/-15 nmol/L; 40 microg/mL pantoprazole, Kd=395+/-12 nmol/L (P<0.05). Pantoprazole also acted on cardiac myofilaments to reduced Ca2+-activated force. CONCLUSIONS: Pantoprazole depresses cardiac contractility in vitro by depression of Ca2+ signaling and myofilament activity. In view of the extensive use of this agent, the effects should be evaluated in vivo.
BACKGROUND: Proton pump inhibitors are used extensively for acid-related gastrointestinal diseases. Their effect on cardiac contractility has not been assessed directly. METHODS AND RESULTS: Under physiological conditions (37 degrees C, pH 7.35, 1.25 mmol/L Ca2+), there was a dose-dependent decrease in contractile force in ventricular trabeculae isolated from end-stage failing human hearts superfused with pantoprazole. The concentration leading to 50% maximal response was 17.3+/-1.3 microg/mL. Similar observations were made in trabeculae from human atria, normal rabbit ventricles, and isolated rabbit ventricular myocytes. Real-time polymerase chain reaction demonstrated the expression of gastric H+/K+-adenosine triphosphatase in human and rabbit myocardium. However, measurements with BCECF-loaded rabbit trabeculae did not reveal any significant pantoprazole-dependent changes of pH(i). Ca2+ transients recorded from field-stimulated fluo 3-loaded myocytes (F/F0) were significantly depressed by 10.4+/-2.1% at 40 microg/mL. Intracellular Ca2+ fluxes were assessed in fura 2-loaded, voltage-clamped rabbit ventricular myocytes. Pantoprazole (40 microg/mL) caused an increase in diastolic [Ca2+]i by 33+/-12%, but peak systolic [Ca2+]i was unchanged, resulting in a decreased Ca2+ transient amplitude by 25+/-8%. The amplitude of the L-type Ca2+ current (I(Ca,L)) was reduced by 35+/-5%, and sarcoplasmic reticulum Ca2+ content was reduced by 18+/-6%. Measurements of oxalate-supported sarcoplasmic reticulum Ca2+ uptake in permeabilized cardiomyocytes indicated that pantoprazole decreased Ca2+ sensitivity (Kd) of sarcoplasmic reticulum Ca2+ adenosine triphosphatase: control, Kd=358+/-15 nmol/L; 40 microg/mL pantoprazole, Kd=395+/-12 nmol/L (P<0.05). Pantoprazole also acted on cardiac myofilaments to reduced Ca2+-activated force. CONCLUSIONS:Pantoprazole depresses cardiac contractility in vitro by depression of Ca2+ signaling and myofilament activity. In view of the extensive use of this agent, the effects should be evaluated in vivo.
Authors: Jeanne-Marie Perotin; James P R Schofield; Susan J Wilson; Jonathan Ward; Joost Brandsma; Fabio Strazzeri; Aruna Bansal; Xian Yang; Anthony Rowe; Julie Corfield; Rene Lutter; Dominick E Shaw; Per S Bakke; Massimo Caruso; Barbro Dahlén; Stephen J Fowler; Ildikó Horváth; Peter Howarth; Norbert Krug; Paolo Montuschi; Marek Sanak; Thomas Sandström; Kai Sun; Ioannis Pandis; Charles Auffray; Bertrand De Meulder; Diane Lefaudeux; John H Riley; Ana R Sousa; Sven-Erik Dahlen; Ian M Adcock; Kian Fan Chung; Peter J Sterk; Paul J Skipp; Jane E Collins; Donna E Davies; Ratko Djukanović Journal: Eur Respir J Date: 2019-06-27 Impact factor: 16.671
Authors: Lisa J Murray; Melissa Gabello; David S Rudolph; Christopher P Farrell; Melissa Morgan; Aaron P Martin; James C Underwood; M Carmen Valenzano; James M Mullin Journal: Dig Dis Sci Date: 2008-11-18 Impact factor: 3.199
Authors: Wolfgang Schillinger; Nina Hörnes; Nils Teucher; Samuel Sossalla; Daniel Sehrt; Klaus Jung; Mark Hünlich; Bernhard Unsöld; Bianca Geiling; Giuliano Ramadori; Reinhard Hilgers; Harald Schwörer; Gerd Hasenfuss Journal: Clin Res Cardiol Date: 2009-03-20 Impact factor: 5.460
Authors: Elizabeth J Bell; Suzette J Bielinski; Jennifer L St Sauver; Lin Y Chen; Mary R Rooney; Nicholas B Larson; Paul Y Takahashi; Aaron R Folsom Journal: Mayo Clin Proc Date: 2021-10 Impact factor: 11.104
Authors: Nigam H Shah; Paea LePendu; Anna Bauer-Mehren; Yohannes T Ghebremariam; Srinivasan V Iyer; Jake Marcus; Kevin T Nead; John P Cooke; Nicholas J Leeper Journal: PLoS One Date: 2015-06-10 Impact factor: 3.240
Authors: Steven P Dunn; Steven R Steinhubl; Deborah Bauer; Richard J Charnigo; Peter B Berger; Eric J Topol Journal: J Am Heart Assoc Date: 2013-01-15 Impact factor: 5.501